Incidence of cardiovascular disease up to 13 year after cancer diagnosis: A matched cohort study among 32 757 cancer survivors

Dounya Schoormans, Pauline A J Vissers, Myrthe P P van Herk-Sukel, Johan Denollet, Susanne S Pedersen, Susanne O Dalton, Nina Rottmann, Lonneke van de Poll-Franse

Research output: Contribution to journalJournal articleResearchpeer-review

101 Downloads (Pure)

Abstract

We examined the incidence of cardiovascular disease (CVD) among 32 757 cancer survivors and age-, gender-, and geographically matched cancer-free controls during a follow-up period of 1-13 years, and explored whetherCVD incidence differed by received cancer treatment, traditional cardiovascular risk factors, age, or gender. Adult 1-year cancer survivors without a history ofCVD diagnosed with breast (n = 6762), prostate (n = 4504), non-Hodgkin (n = 1553), Hodgkin (n = 173), lung and trachea (n = 2661), basal cell carcinoma (BCC; n = 12 476), and colorectal (n = 4628) cancer during 1999-2011 were selected from the Netherlands Cancer Registry and matched to cancer-free controls without a history ofCVD. Drug dispenses and hospitalizations from thePHARMO Database Network were used as proxy forCVD. Data were analyzed using Cox regression analyses. Prostate (HR: 1.17; 95%CI: 1.01-1.35) and lung and trachea (HR: 1.48; 95%CI: 1.10-1.97) cancer survivors had an increased risk for developingCVD compared to cancer-free controls. This increased risk among lung and trachea cancer survivors remained statistically significant after including traditional cardiovascular risk factors and cancer treatment information (HR: 1.41; 95%CI: 1.06-1.89). Among prostate cancer survivors, the increased risk of incidentCVD was limited to those who received hormones and those without traditional cardiovascular risk factors. Breast, non-Hodgkin,BCC, and colorectal cancer survivors showed no increasedCVD risk compared to cancer-free controls. There was an increased risk of incidentCVD among prostate, and lung and trachea cancer survivors compared to age-, gender- and geographically matched cancer-free controls. Studies including longer follow-up periods are warranted to examine whether cancer survivors are at increased risk of long-term incidentCVD.

Original languageEnglish
JournalCancer Medicine
Volume7
Issue number10
Pages (from-to)4952-4963
ISSN2045-7634
DOIs
Publication statusPublished - Oct 2018

Fingerprint

Cohort Studies
Incidence
Neoplasms
Prostate
Non-Hodgkin's Lymphoma
History
Lung
Proxy
Hodgkin Disease
Netherlands
Registries
Colorectal Neoplasms
Prostatic Neoplasms
Regression Analysis
Databases
Hormones

Keywords

  • cancer survivors
  • cardiotoxic treatment
  • cardiovascular disease
  • matched cohort study

Cite this

Schoormans, D., Vissers, P. A. J., van Herk-Sukel, M. P. P., Denollet, J., Pedersen, S. S., Dalton, S. O., ... van de Poll-Franse, L. (2018). Incidence of cardiovascular disease up to 13 year after cancer diagnosis: A matched cohort study among 32 757 cancer survivors. Cancer Medicine, 7(10), 4952-4963. https://doi.org/10.1002/cam4.1754
Schoormans, Dounya ; Vissers, Pauline A J ; van Herk-Sukel, Myrthe P P ; Denollet, Johan ; Pedersen, Susanne S ; Dalton, Susanne O ; Rottmann, Nina ; van de Poll-Franse, Lonneke. / Incidence of cardiovascular disease up to 13 year after cancer diagnosis : A matched cohort study among 32 757 cancer survivors. In: Cancer Medicine. 2018 ; Vol. 7, No. 10. pp. 4952-4963.
@article{50862a6cd8a842848055684bf98d0ac2,
title = "Incidence of cardiovascular disease up to 13 year after cancer diagnosis: A matched cohort study among 32 757 cancer survivors",
abstract = "We examined the incidence of cardiovascular disease (CVD) among 32 757 cancer survivors and age-, gender-, and geographically matched cancer-free controls during a follow-up period of 1-13 years, and explored whetherCVD incidence differed by received cancer treatment, traditional cardiovascular risk factors, age, or gender. Adult 1-year cancer survivors without a history ofCVD diagnosed with breast (n = 6762), prostate (n = 4504), non-Hodgkin (n = 1553), Hodgkin (n = 173), lung and trachea (n = 2661), basal cell carcinoma (BCC; n = 12 476), and colorectal (n = 4628) cancer during 1999-2011 were selected from the Netherlands Cancer Registry and matched to cancer-free controls without a history ofCVD. Drug dispenses and hospitalizations from thePHARMO Database Network were used as proxy forCVD. Data were analyzed using Cox regression analyses. Prostate (HR: 1.17; 95{\%}CI: 1.01-1.35) and lung and trachea (HR: 1.48; 95{\%}CI: 1.10-1.97) cancer survivors had an increased risk for developingCVD compared to cancer-free controls. This increased risk among lung and trachea cancer survivors remained statistically significant after including traditional cardiovascular risk factors and cancer treatment information (HR: 1.41; 95{\%}CI: 1.06-1.89). Among prostate cancer survivors, the increased risk of incidentCVD was limited to those who received hormones and those without traditional cardiovascular risk factors. Breast, non-Hodgkin,BCC, and colorectal cancer survivors showed no increasedCVD risk compared to cancer-free controls. There was an increased risk of incidentCVD among prostate, and lung and trachea cancer survivors compared to age-, gender- and geographically matched cancer-free controls. Studies including longer follow-up periods are warranted to examine whether cancer survivors are at increased risk of long-term incidentCVD.",
keywords = "cancer survivors, cardiotoxic treatment, cardiovascular disease, matched cohort study",
author = "Dounya Schoormans and Vissers, {Pauline A J} and {van Herk-Sukel}, {Myrthe P P} and Johan Denollet and Pedersen, {Susanne S} and Dalton, {Susanne O} and Nina Rottmann and {van de Poll-Franse}, Lonneke",
note = "{\circledC} 2018 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.",
year = "2018",
month = "10",
doi = "10.1002/cam4.1754",
language = "English",
volume = "7",
pages = "4952--4963",
journal = "Cancer Medicine",
issn = "2045-7634",
publisher = "JohnWiley & Sons Ltd.",
number = "10",

}

Schoormans, D, Vissers, PAJ, van Herk-Sukel, MPP, Denollet, J, Pedersen, SS, Dalton, SO, Rottmann, N & van de Poll-Franse, L 2018, 'Incidence of cardiovascular disease up to 13 year after cancer diagnosis: A matched cohort study among 32 757 cancer survivors', Cancer Medicine, vol. 7, no. 10, pp. 4952-4963. https://doi.org/10.1002/cam4.1754

Incidence of cardiovascular disease up to 13 year after cancer diagnosis : A matched cohort study among 32 757 cancer survivors. / Schoormans, Dounya; Vissers, Pauline A J; van Herk-Sukel, Myrthe P P; Denollet, Johan; Pedersen, Susanne S; Dalton, Susanne O; Rottmann, Nina; van de Poll-Franse, Lonneke.

In: Cancer Medicine, Vol. 7, No. 10, 10.2018, p. 4952-4963.

Research output: Contribution to journalJournal articleResearchpeer-review

TY - JOUR

T1 - Incidence of cardiovascular disease up to 13 year after cancer diagnosis

T2 - A matched cohort study among 32 757 cancer survivors

AU - Schoormans, Dounya

AU - Vissers, Pauline A J

AU - van Herk-Sukel, Myrthe P P

AU - Denollet, Johan

AU - Pedersen, Susanne S

AU - Dalton, Susanne O

AU - Rottmann, Nina

AU - van de Poll-Franse, Lonneke

N1 - © 2018 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

PY - 2018/10

Y1 - 2018/10

N2 - We examined the incidence of cardiovascular disease (CVD) among 32 757 cancer survivors and age-, gender-, and geographically matched cancer-free controls during a follow-up period of 1-13 years, and explored whetherCVD incidence differed by received cancer treatment, traditional cardiovascular risk factors, age, or gender. Adult 1-year cancer survivors without a history ofCVD diagnosed with breast (n = 6762), prostate (n = 4504), non-Hodgkin (n = 1553), Hodgkin (n = 173), lung and trachea (n = 2661), basal cell carcinoma (BCC; n = 12 476), and colorectal (n = 4628) cancer during 1999-2011 were selected from the Netherlands Cancer Registry and matched to cancer-free controls without a history ofCVD. Drug dispenses and hospitalizations from thePHARMO Database Network were used as proxy forCVD. Data were analyzed using Cox regression analyses. Prostate (HR: 1.17; 95%CI: 1.01-1.35) and lung and trachea (HR: 1.48; 95%CI: 1.10-1.97) cancer survivors had an increased risk for developingCVD compared to cancer-free controls. This increased risk among lung and trachea cancer survivors remained statistically significant after including traditional cardiovascular risk factors and cancer treatment information (HR: 1.41; 95%CI: 1.06-1.89). Among prostate cancer survivors, the increased risk of incidentCVD was limited to those who received hormones and those without traditional cardiovascular risk factors. Breast, non-Hodgkin,BCC, and colorectal cancer survivors showed no increasedCVD risk compared to cancer-free controls. There was an increased risk of incidentCVD among prostate, and lung and trachea cancer survivors compared to age-, gender- and geographically matched cancer-free controls. Studies including longer follow-up periods are warranted to examine whether cancer survivors are at increased risk of long-term incidentCVD.

AB - We examined the incidence of cardiovascular disease (CVD) among 32 757 cancer survivors and age-, gender-, and geographically matched cancer-free controls during a follow-up period of 1-13 years, and explored whetherCVD incidence differed by received cancer treatment, traditional cardiovascular risk factors, age, or gender. Adult 1-year cancer survivors without a history ofCVD diagnosed with breast (n = 6762), prostate (n = 4504), non-Hodgkin (n = 1553), Hodgkin (n = 173), lung and trachea (n = 2661), basal cell carcinoma (BCC; n = 12 476), and colorectal (n = 4628) cancer during 1999-2011 were selected from the Netherlands Cancer Registry and matched to cancer-free controls without a history ofCVD. Drug dispenses and hospitalizations from thePHARMO Database Network were used as proxy forCVD. Data were analyzed using Cox regression analyses. Prostate (HR: 1.17; 95%CI: 1.01-1.35) and lung and trachea (HR: 1.48; 95%CI: 1.10-1.97) cancer survivors had an increased risk for developingCVD compared to cancer-free controls. This increased risk among lung and trachea cancer survivors remained statistically significant after including traditional cardiovascular risk factors and cancer treatment information (HR: 1.41; 95%CI: 1.06-1.89). Among prostate cancer survivors, the increased risk of incidentCVD was limited to those who received hormones and those without traditional cardiovascular risk factors. Breast, non-Hodgkin,BCC, and colorectal cancer survivors showed no increasedCVD risk compared to cancer-free controls. There was an increased risk of incidentCVD among prostate, and lung and trachea cancer survivors compared to age-, gender- and geographically matched cancer-free controls. Studies including longer follow-up periods are warranted to examine whether cancer survivors are at increased risk of long-term incidentCVD.

KW - cancer survivors

KW - cardiotoxic treatment

KW - cardiovascular disease

KW - matched cohort study

U2 - 10.1002/cam4.1754

DO - 10.1002/cam4.1754

M3 - Journal article

C2 - 30220107

VL - 7

SP - 4952

EP - 4963

JO - Cancer Medicine

JF - Cancer Medicine

SN - 2045-7634

IS - 10

ER -